NEW YORK (GenomeWeb News) – Illumina's MiSeq platform is best positioned to benefit from the growing interest in desktop sequencing, a Piper Jaffray analyst said today.

In a research note analyst William Quirk also called recent speculation that Roche could be again pursuing the San Diego-based company "ridiculous and unfounded."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.